Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California.
Analyst Outlook | Discover analysts' cautious optimism on Inhibrx, with a balanced view reflected in market performance ratings and an average price target range of $40-$60 |
Market Potential | Learn how Inhibrx's novel therapies could capture significant market share in underserved oncology indications, with potential first-mover advantage in chondrosarcoma |
Financial Fortitude | Delve into Inhibrx's robust financial position, bolstered by a $2.2 billion Sanofi deal, providing runway for multiple clinical programs through key milestones |
Pipeline Promise | Explore Inhibrx's innovative oncology pipeline, featuring ozekibart for chondrosarcoma and INBRX-106 for head and neck cancer, poised for pivotal data readouts |
Metrics to compare | INBX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipINBXPeersSector | |
---|---|---|---|---|
P/E Ratio | 0.1x | −0.2x | −0.6x | |
PEG Ratio | - | −0.01 | 0.00 | |
Price / Book | 1.5x | 0.3x | 2.6x | |
Price / LTM Sales | 1,017.7x | 10.3x | 3.0x | |
Upside (Analyst Target) | 7.6% | 235.0% | 51.6% | |
Fair Value Upside | Unlock | 4.7% | 9.3% | Unlock |